Lateral neck dissection for the treatment of synchronous and metachronous lateral neck metastasis of N1b papillary thyroid cancer.

head and neck neoplasms lateral neck dissection metachronous lateral neck dissection metachronous lateral neck dissection papillary thyroid cancer synchronous lateral neck dissection

Journal

Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782

Informations de publication

Date de publication:
2023
Historique:
received: 15 02 2023
accepted: 02 06 2023
medline: 11 7 2023
pubmed: 10 7 2023
entrez: 10 7 2023
Statut: epublish

Résumé

Metachronous lateral neck recurrence after thyroidectomy for N1b papillary thyroid cancer is accompanied by high morbidity and increased difficulty of reoperation. From the perspective of recurrence, the objective of this study was to compare patients who underwent metachronous lateral neck dissection (mLND) despite initial thyroidectomy and patients who underwent synchronous lateral neck dissection (sLND) for papillary thyroid cancer and analyze the risk factors for recurrence after mLND. This retrospective study involved 1,760 patients who underwent lateral neck dissection for papillary thyroid cancer at the Gangnam Severance Hospital, a tertiary medical center in Korea, from June 2005 to December 2016. The primary outcome was structural recurrence, and secondary outcome measures were risk factors of recurrence in the mLND group. A total of 1,613 patients underwent thyroidectomy and sLND at diagnosis. In 147 patients, thyroidectomy alone was performed at the time of diagnosis, and mLND was performed when recurrence to the lateral neck lymph node was confirmed. During a median follow-up of 102.1 months, 110 (6.3%) patients experienced a recurrence. There was no significant difference in the recurrence between the sLND and mLND groups (6.1% vs 8.2%, P=.32). The period from lateral neck dissection to recurrence was longer in the mLND group than in the sLND group (113.6 ± 39.4 months vs 87.0 ± 33.8 months, respectively, P<.001). Age ≥50 years (adjusted HR=5.209, 95% CI=1.359-19.964; P=.02), tumor size >1.45 cm (adjusted HR=4.022, 95% CI=1.036-15.611; P=.04), and lymph node ratio in the lateral compartment (adjusted HR=4.043, 95% CI=1.079-15.148; P=.04) were independent variables predictive of recurrence after mLND. mLND is suitable for treating lateral neck recurrence in patients with N1b papillary thyroid cancer who previously underwent thyroidectomy. Lateral neck recurrence after treatment in patients who underwent mLND was predicted by age, tumor size, and lymph node ratio in the lateral compartment.

Identifiants

pubmed: 37424860
doi: 10.3389/fendo.2023.1166640
pmc: PMC10325561
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1166640

Informations de copyright

Copyright © 2023 Yun, Lee, Lee, Kim, Chang, Lee, Chang and Park.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

CMAJ. 2007 Nov 20;177(11):1357-61
pubmed: 18025426
Endocrine. 2014 Sep;47(1):273-82
pubmed: 24366642
Thyroid. 2012 Nov;22(11):1144-52
pubmed: 23083442
J Clin Endocrinol Metab. 1999 Feb;84(2):458-63
pubmed: 10022401
World J Surg Oncol. 2018 Oct 12;16(1):205
pubmed: 30314503
World J Surg. 2006 May;30(5):833-40
pubmed: 16555024
Medicine (Baltimore). 2018 Dec;97(51):e13435
pubmed: 30572443
J Surg Oncol. 2013 Jul;108(1):47-51
pubmed: 23625380
Am J Surg. 1992 Dec;164(6):671-6
pubmed: 1463122
Ann Surg Oncol. 2016 Sep;23(9):2866-73
pubmed: 27075321
Thyroid. 2018 Mar;28(3):295-300
pubmed: 29373949
Thyroid. 1998 Mar;8(3):197-202
pubmed: 9545105
Ann Surg. 1953 Jul;138(1):33-8
pubmed: 13058300
Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):784-91
pubmed: 19240234
Cancer. 2016 Dec 15;122(24):3754-3759
pubmed: 27517675
Oral Oncol. 2016 Nov;62:109-113
pubmed: 27865362
JAMA Otolaryngol Head Neck Surg. 2014 Apr;140(4):317-22
pubmed: 24557566
Arch Endocrinol Metab. 2016 Oct 10;60(5):492-499
pubmed: 27737333
Laryngoscope. 2010 Sep;120(9):1716-7
pubmed: 20803739
Oncologist. 2013;18(2):157-62
pubmed: 23345543
Nat Rev Endocrinol. 2016 Nov;12(11):646-653
pubmed: 27418023
Endocr Relat Cancer. 2004 Mar;11(1):131-9
pubmed: 15027890
Clin Endocrinol (Oxf). 2014 Jul;81 Suppl 1:1-122
pubmed: 24989897
Ann Surg Oncol. 2015 Jan;22(1):117-24
pubmed: 25034816
Ann Surg. 2007 Mar;245(3):366-78
pubmed: 17435543
Ann Surg Oncol. 2017 Nov;24(12):3609-3616
pubmed: 28822118
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
World J Surg. 2012 Jun;36(6):1274-8
pubmed: 22270990
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
Lancet. 2016 Dec 3;388(10061):2783-2795
pubmed: 27240885
World J Surg. 2007 May;31(5):905-15
pubmed: 17219265
Otolaryngol Head Neck Surg. 2012 Jul;147(1):15-9
pubmed: 22399280

Auteurs

Hyeok Jun Yun (HJ)

Department of Surgery, Institute of Refractory Thyroid Cancer, Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.

Jin Seok Lee (JS)

Department of Surgery, Institute of Refractory Thyroid Cancer, Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.

Jun Sung Lee (JS)

Department of Surgery, Institute of Refractory Thyroid Cancer, Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.

Seok Mo Kim (SM)

Department of Surgery, Institute of Refractory Thyroid Cancer, Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.

Hojin Chang (H)

Department of Surgery, Institute of Refractory Thyroid Cancer, Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.

Yong Sang Lee (YS)

Department of Surgery, Institute of Refractory Thyroid Cancer, Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.

Hang-Seok Chang (HS)

Department of Surgery, Institute of Refractory Thyroid Cancer, Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.

Cheong Soo Park (CS)

Department of Surgery, CHA Ilsan Medical Center, Goyang-si, Republic of Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH